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Abstract
Purpose: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are
characterized with large isolated dwell times at the first or last dwell position of each catheter. The potential of
catheter shifts relative to the target and organs at risk in these plans may lead to a more significant change in
delivered dose to the volumes of interest relative to plans with more uniform dwell times. Material and
methods: This study aims to determine if the Nucletron Oncentra dwell time deviation constraint (DTDC)
parameter can be optimized to improve the robustness of high-dose-rate (HDR) prostate brachytherapy plans
to catheter displacements. A set of 10 clinically acceptable prostate plans were re-optimized with a DTDC
parameter of 0 and 0.4. For each plan, catheter displacements of 3, 7, and 14 mm were retrospectively applied
and the change in dose volume histogram (DVH) indices and conformity indices analyzed. Results: The
robustness of clinically acceptable prostate plans to catheter displacements in the caudal direction was found
to be dependent on the DTDC parameter. A DTDC value of 0 improves the robustness of planning target
volume (PTV) coverage to catheter displacements, whereas a DTDC value of 0.4 improves the robustness of
the plans to changes in hotspots. Conclusions: The results indicate that if used in conjunction with a pre-
treatment catheter displacement correction protocol and a tolerance of 3 mm, a DTDC value of 0.4 may
produce clinically superior plans. However, the effect of the DTDC parameter in plan robustness was not
observed to be as strong as initially suspected.
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Abstract 
Purpose: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are characterized 
with large isolated dwell times at the first or last dwell position of each catheter. The potential of catheter shifts relative 
to the target and organs at risk in these plans may lead to a more significant change in delivered dose to the volumes 
of interest relative to plans with more uniform dwell times. 
Material and methods: This study aims to determine if the Nucletron Oncentra dwell time deviation constraint 
(DTDC) parameter can be optimized to improve the robustness of high-dose-rate (HDR) prostate brachytherapy plans 
to catheter displacements. A set of 10 clinically acceptable prostate plans were re-optimized with a DTDC parameter 
of 0 and 0.4. For each plan, catheter displacements of 3, 7, and 14 mm were retrospectively applied and the change in 
dose volume histogram (DVH) indices and conformity indices analyzed. 
Results: The robustness of clinically acceptable prostate plans to catheter displacements in the caudal direction 
was found to be dependent on the DTDC parameter. A DTDC value of 0 improves the robustness of planning target 
volume (PTV) coverage to catheter displacements, whereas a DTDC value of 0.4 improves the robustness of the plans 
to changes in hotspots. 
Conclusions: The results indicate that if used in conjunction with a pre-treatment catheter displacement correction 
protocol and a tolerance of 3 mm, a DTDC value of 0.4 may produce clinically superior plans. However, the effect of 
the DTDC parameter in plan robustness was not observed to be as strong as initially suspected. 
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Purpose 
Prostate cancer is the most common male malignan-
cy in the Western world, and as life expectancy increase, 
the prevalence is also expected to increase in an aging 
population [1]. Radiotherapy is an important therapeutic 
modality for the treatment of patients with localized or 
locally advanced prostate cancer [2] utilizing both exter-
nal beam radiotherapy (EBRT) and brachytherapy. Over 
the last few decades, significant advances in technology 
related to high-dose-rate (HDR) brachytherapy have seen 
an increase in its use as a localized boost to EBRT of the 
prostate. 
An important technological advancement in HDR 
brachytherapy is the evolution from forward planning to 
inverse planning techniques [3,4,5]. The inverse planning 
optimization algorithm currently implemented in the Nu-
cletron Oncentra (Nucletron B.V., Veenendaal, The Neth-
erlands) brachytherapy treatment planning system (TPS) 
is the inverse planning simulated annealing (IPSA) opti-
mization algorithm. Inverse planning simulated annealing 
is based on contoured anatomy and optimizes dwell times 
using a simulated annealing algorithm [6]. The algorithm 
is constrained by user specific surface and volumetric dose 
constraints for both the target volume and organs at risk to 
calculate clinically acceptable treatment plans [7]. 
Inverse planning simulated annealing optimized 
brachytherapy treatment plans are characterized with 
large isolated dwell times at the first or last dwell posi-
tion of each catheter. The central dwell positions how-
ever consist of extremely short, or zero, dwell times [8]. 
There is concern amongst users that these large isolated 
dwell times may lead to hot spots, either inside or outside 
the target. Also, the potential of catheter shifts relative to 
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the target and organs at risk may lead to a more signifi-
cant change in delivered dose to the volumes of interest 
relative to plans with more uniform dwell times. Recent-
ly, the Nucletron Oncentra TPS has added the dwell time 
deviation constraint (DTDC) parameter to the IPSA opti-
mization process. This parameter constrains the allowable 
dwell times in the optimization process and can be set to 
a value between 0 and 1 in increments of 0.1. A value of 
0 corresponds to completely unrestricted dwell times and 
a value of 1 results in homogeneous dwell times [9]. 
The displacement of catheters relative to the target and 
organs at risk during the time between imaging and pa-
tient treatment has been reported by a number of groups 
[10,11,12,13]. The displacements have predominantly 
been reported along the patient longitudinal axis and in 
the caudal direction [10] primarily due to acute edema 
between the prostate and perineal skin [14]. Previous 
work from our group [11] demonstrated a median cath-
eter displacement of 7.5 mm in caudal direction (range 
2.9-23.9 mm) in the time from planning CT to treatment 
(approximately 1-3 hours). Tiong et al. [10] have reported 
significant adverse effects on the tumor control probabil-
ity for catheter displacements larger than 3 mm, includ-
ing underdosage of the target and overdosage to critical 
structures. Due to these findings, our department has im-
plemented a clinical protocol, in which internal catheter 
positions are verified and corrected immediately prior to 
treatment delivery with a tolerance of 3 mm. 
This study aims to determine if the DTDC parameter 
can be optimized to improve the robustness of HDR pros-
tate brachytherapy plans to catheter displacements rela-
tive to patient anatomy. A set of 10 clinically acceptable 
prostate plans were re-optimized with a DTDC param-
eter of 0 and 0.4. The values of 0 and 0.4 were chosen to 
reflect the change that is currently occurring in our clini-
cal protocol. For each plan, catheter displacements of 3, 7, 
and 14 mm were retrospectively applied, and the change 
in DVH indices and conformity indices analyzed. 
Material and methods 
Initial plans 
A set of 10 clinical prostate HDR brachytherapy plans 
were chosen for analysis. These CT plans were creat-
ed between 2012 and 2015 on the Nucletron Oncentra 
Brachytherapy TPS (v4.3, Nucletron B.V., Veenendaal, 
The Netherlands). The prostate planning target volume 
(PTV), urethra, and rectum were all contoured by the 
same radiation oncologist at the time of treatment. Pros-
tate volumes varied between 25.1 and 59.4 cm3 and the 
number of catheters used was between 14 and 24. All pa-
tients received 2 fractions of 9.5 Gy with 2 weeks between 
fractions. Catheter insertion (using Oncosmart, ProGuide 
Sharp Needle, 6F, Nucletron B.V., Veenendaal, The Neth-
erlands), CT scan, planning, and treatment are all per-
formed on the same day, and the mean time between the 
planning CT and treatment was 182 minutes. 
IPSA optimization and DTDC 
Each plan was optimized using the IPSA algorithm 
using the parameters outlined in Table 1. As per clinical 
protocol, plans were initially optimized with the DTDC 
parameter set to 0. The plans were then re-optimized with 
the DTDC parameter set to 0.4 and all other parameters 
kept constant. The dwell time characteristics of each plan 
were then compared using the plan modulation index 
(M), as defined by Smith et al. [9]. The plan modulation 
index is defined as the maximum deviation of dwell time 
from the average dwell time for each catheter, normal-
ized to the maximum dwell time for the treatment plan, 
averaged over all catheters in the plan. 
Catheter displacements 
Catheter displacements in the caudal direction were 
then simulated for each plan. Offsets of 3, 7, and 14 mm 
were performed. Displacements of this magnitude were 
chosen as they corresponded to clinically relevant cath-
eter displacements, as found in a previous study by our 
group [11]. Our center has implemented a clinical pro-
tocol, in which catheter displacements ≥ 3 mm are cor-
rected for, immediately prior to treatment by altering the 
indexer length at the treatment console. Implanting the 
catheters past the prostate base into the bladder allowed 
for extra dwell positions beyond the prostate in the event 
of a caudal shift. Physical re-insertion was not performed. 
Plan analysis 
All patient plans were assessed by evaluating dose 
volume histogram (DVH) indices and dose quality indi-
ces. Dose volume histogram indices used for plan evalu-
ation are outlined in Table 2. Furthermore, a normal tis-
sue (NT) contour was created by adding a 2 mm margin 
around the PTV and subtracting this expanded contour 
from the external contour, e.g. NT = Body – (PTV + 2 mm). 
These parameters were automatically calculated by the 
Table 1. Inverse planning simulated annealing (IPSA) optimization parameters used for patient plan optimiza-
tion 
ROI Usage Surface Volume
Weight Min (cGy) Max (cGy) Weight Weight Min (cGy) Max (cGy) Weight
Prostate PTV 100 950 1425 100 100 100 950 30
Rectum Organ 665 50 50 475 50
Urethra Organ 120 950 998 50 50 950 998 50
PTV – planning target volume 
Journal of Contemporary Brachytherapy (2016/volume 8/number 3)
IPSA optimized plan robustness 205
TPS and are highly dependent on the size of the histo-
gram bin used for calculation [8]. Because of this, a con-
formity index (CI), a dose inhomogeneity index (DHI), 
and an overdose volume index (ODI) were also calculat-
ed for each plan. 
The CI used in this study is the one introduced by 
van’t Riet et al. [15] and is shown in Equation 1: 
CI = VT,refVT
VT,ref
Vref
×   (1),
where VT,ref is the volume of the PTV receiving a dose 
greater than or equal to the 100% isodose, VT is the vol-
ume of the PTV, and Vref is the volume of the 100% iso-
dose. The DHI parameter gives an indication of the ho-
mogeneity of the dose within the PTV, which was first 
introduced by Wu et al. [16] and is shown in Equation 2: 
DHI = VT,ref – VT,1.5refVT,ref  
(2),
where VT,1.5ref is the volume of the PTV receiving a dose 
greater than or equal to the 150% isodose, and VT,ref is as 
described above. Finally, the ODI parameter [17] indi-
cates the amount of high dose (greater than 200%) within 
the PTV: 
ODI = VT,2refVT,ref  
(3),
where VT,2ref is the volume of the PTV receiving a dose 
greater than or equal to the 200% isodose. 
The change in DVH and dose quality indices was then 
calculated as a function of catheter displacement for both 
DTDC values of 0 and 0.4. The change in these indices 
with increasing catheter displacement gives an indication 
of the robustness of the plans to changes in catheter po-
sition relative to the targets and organs at risk between 
planning CT and treatment. Statistical significance be-
tween the DTDC values was verified using a paired t-test 
with α = 0.05 (corresponding to a 5% significance level). 
Results 
Initial clinical plans 
Initial clinical prostate plans IPSA optimized with 
a DTDC value of 0 produced a large spread of dwell 
times, relative to those plans optimized with a DTDC 
value of 0.4. The plan modulation index (M) for each 
plan variant is given in Table 3 along with the total dwell 
time, normalized to the air kerma strength of the source. 
The average M for the 0 DTDC case (± 1 SD) was equal 
to 0.44 ± 0.07, whereas for the 0.4 DTDC case M = 0.20 
± 0.06. The effect of increasing the DTDC parameter is 
to limit the maximum dwell time in any catheter; this is 
reflected by the decreasing value of M, as more homoge-
neous dwell time distribution is created within each cath-
Table 2. Clinically acceptable dose volume histo-
gram (DVH) indices 
Volume type Dose (%) Dose (cGy) Volume (%)
PTV 100 950 ≥ 90
PTV 150 1425 < 30
PTV 200 1900 < 15
Rectum 70 665 0
Urethra 120 1140 0
PTV – planning target volume 
Table 3. Plan modulation index (M) and normali-
zed total dwell time (cGy-1cm-2) 
Patient Plan modulation index 
(M)
Normalized total dwell 
time (cGy-1cm-2)
DTDC 0 DTDC 0.4 DTDC 0 DTDC 0.4
1 0.48 0.09 8.32 × 10-6 7.73 × 10-6
2 0.34 0.23 2.75 × 10-6 2.55 × 10-6
3 0.43 0.25 2.57 × 10-6 2.33 × 10-6
4 0.41 0.23 10.44 × 10-6 9.82 × 10-6
5 0.57 0.17 15.27 × 10-6 14.32 × 10-6
6 0.43 0.18 12.45 × 10-6 12.34 × 10-6
7 0.42 0.24 6.32 × 10-6 6.12 × 10-6
8 0.48 0.19 8.72 × 10-6 8.29 × 10-6
9 0.40 0.21 8.37 × 10-6 7.80 × 10-6
10 0.44 0.20 7.27 × 10-6 6.80 × 10-6
DTDC – dwell time deviation constraint 
Table 4. Initial dose volume histogram (DVH) and 
dose indices before catheter displacement 
Parameter DTDC 0 DTDC 0.4 p
PTV V100% 92.9 ± 1.9% 93.4 ± 1.7% ≤ 0.2620
PTV V150% 18.9 ± 3.6% 23.0 ± 3.7% ≤ 0.0001
PTV V200% 7.5 ± 1.6% 9.0 ± 1.4% ≤ 0.0002
Rectum V70% 0.1 ± 0.1% 0.1 ± 0.1% ≤ 0.3498
Urethra V120% 10.4 ± 5.6% 5.9 ± 5.9% ≤ 0.0421
NT V100% 11.0 ± 3.0 cc 5.7 ± 1.9 cc ≤ 0.0001
NT V150% 3.3 ± 1.4 cc 1.2 ± 0.7 cc ≤ 0.0001
NT V200% 1.5 ± 0.2 cc 0.5 ± 0.3 cc ≤ 0.0018
CI 0.691 ± 0.046 0.748 ± 0.042 ≤ 0.0002
DHI 0.204 ± 0.039 0.246 ± 0.038 ≤ 0.0001
ODI 0.081 ± 0.018 0.097 ± 0.014 ≤ 0.0004
PTV – planning target volume, NT – normal tissue, CI – conformity index, 
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%, 
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%, 
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation 
constraint 
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eter. The total dwell time, normalized to the air kerma 
strength of the source was also seen to decrease for plans 
optimized with a DTDC value of 0.4, relative to a DTDC 
of 0. This is due to the reduction in large isolated dwell 
times at the first or last dwell positions of each catheter. 
Table 4 shows the change in DVH and dose quali-
ty indices when re-optimizing the plans with a DTDC 
parameter of 0.4. By changing the DTDC value to 0.4, 
the coverage of the PTV is improved, as reflected by the 
increase in PTV V100% and CI, however, only the differ-
ence in CI was found to be statistically significant. Statis-
tically significant reductions in NT V100%, NT V150%, and 
NT V200% were also found when changing DTDC from 0 
to 0.4. This, along with the improvement in CI, is due to 
the reduction in the large isolated dwell times just outside 
of the PTV, which are delivering higher doses to the ad-
jacent healthy tissue. On the other hand, there is a statis-
tically significant increase in PTV V150%, PTV V200%, DHI, 
and ODI for DTDC 0.4 versus DTDC 0. The rectum V150% 
was largely unaffected by the DTDC change, and a small 
reduction in the urethra V120% was observed. 
Effect of catheter displacements 
The effect of catheter displacements on DVH and 
dose quality indices are shown in Tables 5, 6, and 7 for 
catheter shifts of 3, 7, and 14 mm, respectively. Overall, 
a DTDC value of 0 improves the robustness of PTV cover-
age to catheter displacements relative to a DTDC value of 
0.4. This is reflected in the smaller changes in PTV V100% 
(Figure 1) and CI (Figure 2) for all three catheter displace-
ment values. The dwell positions moving out of the PTV 
in the DTDC 0 plans have smaller weights relative to 
those in the DTDC 0.4 plans, resulting in smaller changes 
in PTV V100% and CI with catheter displacement. 
Conversely, a DTDC value of 0.4 improves the robust-
ness of the plans to changes in hotspots, reflected by sta-
tistically significant differences in changes to PTV V150%, 
PTV V200% (Figure 3), DHI, and ODI (Figure 4) compared 
to plans optimized with a DTDC value of 0 for catheter 
displacements up to 14 mm. This behavior can be ex-
plained by considering that the isolated dwell times at the 
end of the catheters often exist just outside the PTV be-
Table 5. Change in dose volume histogram (DVH) 
and dose indices for a 3 mm catheter displacement 
Parameter DTDC 0 DTDC 0.4 p
PTV V100% 0.788 ± 0.751% –1.299 ± 0.916% ≤ 0.0001
PTV V150% 1.786 ± 1.540% 0.146 ± 0.537% ≤ 0.0009
PTV V200% 1.051 ± 0.829% –0.034 ± 0.183% ≤ 0.0021
Rectum V70% 0.078 ± 0.081% 0.080 ± 0.090% ≤ 0.8905
Urethra V120% –5.628 ± 4.878% –4.019 ± 5.047% ≤ 0.0088
NT V100% –1.042 ± 1.314 cc 1.314 ± 1.661 cc ≤ 0.0454
NT V150% –1.033 ± 0.893 cc 0.468 ± 0.504 cc ≤ 0.0001
NT V200% –0.568 ± 0.674 cc 0.171 ± 0.318 cc ≤ 0.0052
CI 0.002 ± 0.017 –0.024 ± 0.022 ≤ 0.0011
DHI 0.017 ± 0.005 0.005 ± 0.006 ≤ 0.0033
ODI 0.011 ± 0.008 0.001 ± 0.002 ≤ 0.0035
PTV – planning target volume, NT – normal tissue, CI – conformity index, 
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%, 
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%, 
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation 
constraint 
Table 6. Change in dose volume histogram (DVH) 
and dose indices for a 7 mm catheter displacement 
Parameter DTDC 0 DTDC 0.4 p
PTV V100% –2.803 ± 2.516% –8.99 ± 2.283% ≤ 0.0001
PTV V150% 2.199 ± 2.670% –1.262 ± 1.158% ≤ 0.0002
PTV V200% 1.255 ± 1.260% –0.689 ± 0.427% ≤ 0.0008
Rectum V70% 0.271 ± 0.324% 0.265 ± 0.324% ≤ 0.7793
Urethra V120% –6.461 ± 5.879% –4.333 ± 6.804% ≤ 0.0205
NT V100% 1.072 ± 3.121 cc 4.381 ± 1.996 cc ≤ 0.0189
NT V150% –0.399 ± 1.639 cc 1.507 ± 0.753 cc ≤ 0.0041
NT V200% –0.471 ± 0.940 cc 0.641 ± 0.517 cc ≤ 0.0014
CI –0.046 ± 0.044 –0.136 ± 0.046 ≤ 0.0005
DHI 0.029 ± 0.024 0.011 ± 0.016 ≤ 0.0007
ODI 0.016 ± 0.012 0.002 ± 0.004 ≤ 0.0020
PTV – planning target volume, NT – normal tissue, CI – conformity index, 
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%, 
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%, 
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation 
constraint 
Table 7. Change in dose volume histogram (DVH) 
and dose indices for a 14 mm catheter displacement 
Parameter DTDC 0 DTDC 0.4 p
PTV V100% –18.69 ± 5.197% –25.74 ± 5.313% ≤ 0.0003
PTV V150% 0.522 ± 3.343% –3.589 ± 2.063% ≤ 0.0001
PTV V200% 0.566 ± 1.455% –1.628 ± 0.786% ≤ 0.0005
Rectum V70% 0.690 ± 0.917% 0.665 ± 0.956% ≤ 0.4049
Urethra V120% –4.657 ± 7.543% –0.592 ± 10.624% ≤ 0.0523
NT V100% 8.928 ± 4.198 cc 13.495 ± 2.333 cc ≤ 0.0002
NT V150% 1.582 ± 1.210 cc 3.981 ± 1.197 cc ≤ 0.0008
NT V200% 0.453 ± 0.786 cc 1.756 ± 0.747 cc ≤ 0.0036
CI –0.251 ± 0.072 –0.352 ± 0.064 ≤ 0.0003
DHI 0.056 ± 0.040 0.041 ± 0.039 ≤ 0.0013
ODI 0.027 ± 0.018 0.013 ± 0.010 ≤ 0.0043
PTV – planning target volume, NT – normal tissue, CI – conformity index, 
DHI – dose inhomogeneity index, ODI – overdose index, V100%, V150%, V200%, 
V70%, V120% – volume of relevant structure receiving 100%, 150%, 200%, 70%, 
and 120% of the prescribed isodose, respectively, DTDC – dwell time deviation 
constraint 
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Fig. 1. The change in PTV V100% as a function of catheter 
displacement for plans optimized with DTDC set to 0 and 
0.4 (error bars showing 95% confidence interval) 
0.05
0.00
–0.05
–0.10
–0.15
–0.20
–0.25
–0.30
–0.35
–0.40
–0.45
 0 2 4 6 8 10 12 14 16
Catheter displacement (mm)
 DTDC 0         DTDC 0.4
C
ha
ng
e 
in
 C
I
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Fig. 2. The change in PTV V200% as a function of catheter 
displacement for plans optimized with DTDC set to 0 and 
0.4 (error bars showing 95% confidence interval) 
fore a catheter shift is implemented. Therefore, the V150% 
and V200% volumes are surrounding these dwell positions 
and, as a catheter shift is implemented, they move further 
away from the PTV and into healthy tissue. 
For a catheter displacement of 3 mm, plans optimized 
with a DTDC value of 0.4 were found to be more robust in 
terms of NT V100%, NT V150%, and NT V200%. Conversely, 
for larger catheter shifts of 7 and 14 mm, the plans op-
timized with DTDC 0 were more robust. This is due to 
the fact that for a catheter shift of 3 mm, one of the large 
isolated dwell positions in the DTDC 0 plans moves into 
the normal tissue. However, for larger shifts, subsequent 
dwell positions moving into the normal tissue have sig-
nificantly smaller dwell times compared to those in the 
DTDC 0.4 plans, resulting in smaller changes in NT V100%, 
NT V150%, and NT V200%. 
The urethra V120% was more sensitive to catheter 
displacements than the rectum V70% for both values of 
DTDC. A DTDC value of 0.4 improved the robustness of 
the plans to changes in urethra V120% compared to plans 
optimized with a DTDC value of 0, with statistically sig-
nificant differences for catheter displacements of 3 and 
7 mm. There was also no statistically significant differ-
ence found between DTDC values for the rectum V70%. 
Discussion 
As expected, the plan modulation index (M) was 
observed to decrease with an increased value of DTDC. 
The calculated values of M = 0.44 ± 0.07 (DTDC = 0) and 
M = 0.20 ± 0.06 (DTDC = 0.4) are in close agreement with 
those found in a previous study by Smith et al. [9]. The in-
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crease value of DTDC was also observed to increase the 
PTV V100%, V150%, and V200%. The increase in PTV V150% of 
4% and PTV V200% of 1.5% when changing the DTDC value 
from 0 to 0.4 was also observed in the same study [9]. This 
increase resulted in DVH indices that were still clinically 
acceptable for treatment according to our local protocol as 
outlined in Table 2. 
Contrary to expectation, the DTDC value of 0 pro-
duced plans that were more robust to catheter displace-
ments in terms of target coverage. However, for a catheter 
displacement of 3 mm, the average CI was 0.693 ± 0.049 
and 0.723 ± 0.045 for DTDC = 0 and DTDC = 0.4, respec-
tively. Our center has implemented a clinical protocol, in 
which catheter displacements ≥ 3 mm are corrected for, 
immediately prior to treatment by adjusting the index-
er length on the treatment control system. Therefore, if 
used in combination with this catheter correction proto-
col, plans optimized with a DTDC value of 0.4 may be 
clinically superior to those optimized with DTDC = 0, 
especially when considering that using a DTDC value of 
0.4 improves robustness to changes in hotspots and dose 
to OARs and healthy tissue. 
One recent advance in the field of HDR prostate 
brachytherapy has been the use of 3D trans-rectal ultra-
sound (TRUS) based treatment planning [18]. The use of 
this technique has been shown to significantly reduce 
the time between imaging and treatment compared to 
CT based treatment planning. Milickovic et al. [18] have 
shown that for an average time between imaging and 
treatment of 51.2 minutes, the average needle displace-
ment was found to be 1 mm. This displacement is small 
relative to those noted in other studies [11,14], and is 
likely due to the reduction in time between imaging and 
treatment. Therefore, one current initiative of our group 
is to reduce the time between imaging and treatment, and 
the introduction of 3D TRUS based planning is being in-
vestigated. 
A previous study by our group [11] has shown that 
catheter displacements in the cranial direction occurred 
for only 3 of 48 cases, with the remainder occurring in 
the caudal direction. One limitation of this study is that 
catheter displacements were only considered along the 
longitudinal axis in the caudal direction. Catheter shifts 
in the lateral and anterior-posterior directions due to ede-
ma were also not considered. 
A further limitation is that only two values of DTDC 
were considered. Preliminary calculations showed that 
small changes in DTDC, e.g. from 0.2-0.4 do not signifi-
cantly affect the robustness of the plans to catheter dis-
placements. Furthermore, values of 0 and 0.4 were cho-
sen to reflect the change that is currently occurring in our 
clinical protocol. Historically, plans have been optimized 
using a DTDC value of 0; however previous studies [9] 
have shown that a DTDC value of 0.4 gives plan modula-
tion equivalent to graphical optimization without signifi-
cantly compromising plan quality. 
Conclusions 
The results of this study indicate that the robustness 
of clinically acceptable prostate plans to catheter displace-
ments in the caudal direction are dependent on the DTDC 
parameter. A DTDC value of 0 improves the robustness 
of PTV coverage to catheter displacements relative to 
a DTDC value of 0.4. Whereas a DTDC value of 0.4 im-
proves the robustness of the plans to changes in hotspots 
compared to a DTDC value of 0. For a catheter displace-
ment of 3 mm, plans optimized with a DTDC value of 
0.4 were found to be more robust in terms of the dose 
to normal tissue. However, for larger catheter shifts, the 
plans optimized with DTDC 0 were more robust, due to 
larger shifts moving relatively small weight dwell posi-
tions into the normal tissue compared to the DTDC 0.4 
plans. When used in combination with a pre-treatment 
catheter displacement correction protocol and a tolerance 
of 3 mm, a DTDC value of 0.4 may produce clinically su-
perior plans. 
In future work, attempts will be made to measure the 
actual dwell times delivered by the afterloader as com-
pared to those calculated by the TPS for a range of DTDC 
values and the effect on the dose examined. 
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